Wednesday, February 10, 2010, 2:28pm SGT - The Singapore stock market closes in 2 hours and 32 minutes.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

ARYx Therapeutics, Inc. (ARYX)

At 5:00AM SGT: 2.95 USD  Up 0.02 (0.68%)  
 MORE ON ARYX 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 ARYx Therapeutics, Inc. (NGM:ARYX) Delayed quote dataEdit
After Hours: 2.95 0.00 (0.00%) as of 5:34am SGT on 02/10/10
Last Trade:2.95 USD
Trade Time:5:00AM SGT
Change:Up 0.02 (0.68%)
Prev Close:2.93
Open:2.98
Bid:2.02 x 100
Ask:3.56 x 100
1y Target Est:6.38
Day's Range:2.93 - 3.03
52wk Range:1.90 - 6.32
Volume:42,778
Avg Vol (3m):76,068.3
Market Cap:81.38M
P/E (ttm):N/A
EPS (ttm):-1.54
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
Use Y! Toolbar to track stocks
 Add ARYX to Portfolio   Download Data

 HEADLINES 
•Aryx gets FDA guidance on blood clot drug that failed trial
at bizjournals.com (Wed, Jan 6)
•ARYX THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Tue, Jan 5)
•ARYx Therapeutics Receives Guidance on Anticoagulant Agent Tecarfarin
Business Wire (Tue, Jan 5)
•ARYX THERAPEUTICS, INC. Financials
EDGAR Online Financials (Wed, Nov 18)
•Results From Phase 2b Study on Atrial Fibrillation Agent Reviewed at American Heart Association
Business Wire (Wed, Nov 18)
•New Star Analyst Rankings for ARYx Therapeutics, Inc.
StarMine (Sun, Nov 15)
•ARYX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
EDGAR Online (Fri, Nov 13)
•Aryx Therapeutics reports $8.2M loss
at bizjournals.com (Fri, Nov 13)
•ARYx Therapeutics Reports Third Quarter 2009 Results
Business Wire (Thu, Nov 12)
•Q3 2009 ARYx Therapeutics Earnings Release - Time Not Supplied
CCBN (Thu, Nov 12)
More Headlines for ARYX...
 ANALYST 
EPS Est (next year) (Dec-09) :-1.20
EPS Est (in 2 years) (Dec-10) :-0.27
Avg Rec (current)*:1.3
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of product candidates designed to eliminate known safety issues associated with commercial drugs using its RetroMetabolic Drug Design technology.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices